What is it about?
This meta-analysis investigated the combined effect of SGLT2i and metformin on the levels of inflammatory molecules in diabetic patients. Our systematic review and meta-analysis demonstrated that this combined treatment regimen effectively reduces CRP or hs-CRP, TNF-α, leptin, uric acid, and eGFR levels in diabetic patients but has no effect on adiponectin levels. Therefore, the meta-analysis suggests that the combined treatment regimen may help improve inflammation levels, possibly facilitating blood glucose control and improving their prognosis.
Featured Image
Photo by Roberto Sorin on Unsplash
Why is it important?
Our meta-analysis focused on this combined treatment effect on inflammation levels in diabetic patients. The combination significantly reduced the levels of inflammatory metrics in diabetic patients, suggesting the higher benefits of the combination in controlling the inflammatory response and reducing complications in diabetes than those of a single drug. Thus, these results provide an evidence-based approach for the clinical use of the two drugs in patients with diabetes.
Perspectives
I hope this article is interesting and meaningful. It could provide new directions in the treatment of patients with type 2 diabetes and improve patient outcomes.
Yang Cao
Shanxi Medical University
Read the Original
This page is a summary of: Effect of SGLT2 Inhibitors and Metformin on Inflammatory and Prognostic
Biomarkers in Type 2 Diabetes Patients, Endocrine Metabolic & Immune Disorders - Drug Targets, April 2023, Bentham Science Publishers,
DOI: 10.2174/1871530322666220827150054.
You can read the full text:
Contributors
The following have contributed to this page
